JP2005528099A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528099A5 JP2005528099A5 JP2004508275A JP2004508275A JP2005528099A5 JP 2005528099 A5 JP2005528099 A5 JP 2005528099A5 JP 2004508275 A JP2004508275 A JP 2004508275A JP 2004508275 A JP2004508275 A JP 2004508275A JP 2005528099 A5 JP2005528099 A5 JP 2005528099A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- light chain
- variable domain
- domain sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004965 antibodies Human genes 0.000 claims 65
- 108090001123 antibodies Proteins 0.000 claims 65
- 210000004408 Hybridomas Anatomy 0.000 claims 20
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 11
- 210000004027 cells Anatomy 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 5
- 102400000401 Latency-associated peptide Human genes 0.000 claims 4
- 101800001155 Latency-associated peptide Proteins 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 102000005614 monoclonal antibodies Human genes 0.000 claims 3
- 108010045030 monoclonal antibodies Proteins 0.000 claims 3
- 101700051744 CLE-1 Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000001419 dependent Effects 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 229920000406 phosphotungstic acid polymer Polymers 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 206010001843 Alport's syndrome Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 102100009791 COL4A5 Human genes 0.000 claims 1
- 101710038499 COL4A5 Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 229920001405 Coding region Polymers 0.000 claims 1
- 206010023421 Kidney fibrosis Diseases 0.000 claims 1
- 206010023825 Laryngeal cancer Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010034811 Pharyngeal cancer Diseases 0.000 claims 1
- 208000005069 Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 201000008006 pharynx cancer Diseases 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
Claims (59)
- モノクローナル抗体であって、(a)αvβ6に特異的に結合し;かつ(b)潜伏関連ペプチド(LAP)へのαvβ6の結合を、10D5のIC50値未満のIC50値で阻害する、抗体。
- 前記抗体が、ハイブリドーマ6.1A8(ATCC登録番号PTA−3647)によって産生される抗体と同じ重鎖ポリペプチド配列および軽鎖ポリペプチド配列を含む、請求項1に記載の抗体。
- 前記抗体が、ハイブリドーマ6.3G9(ATCC登録番号PTA−3649)によって産生される抗体と同じ重鎖ポリペプチド配列および軽鎖ポリペプチド配列を含む、請求項1に記載の抗体。
- 前記抗体が、ハイブリドーマ6.8G6(ATCC登録番号PTA−3645)によって産生される抗体と同じ重鎖ポリペプチド配列および軽鎖ポリペプチド配列を含む、請求項1に記載の抗体。
- 前記抗体が、ハイブリドーマ6.2B1(ATCC登録番号PTA−3646)によって産生される抗体と同じ重鎖ポリペプチド配列および軽鎖ポリペプチド配列を含む、請求項1に記載の抗体。
- 前記抗体が、ハイブリドーマ7.1G10(ATCC登録番号PTA−3898)によって産生される抗体と同じ重鎖ポリペプチド配列および軽鎖ポリペプチド配列を含む、請求項1に記載の抗体。
- 前記抗体が、ハイブリドーマ7.7G5(ATCC登録番号PTA−3899)によって産生される抗体と同じ重鎖ポリペプチド配列および軽鎖ポリペプチド配列を含む、請求項1に記載の抗体。
- 前記抗体が、ハイブリドーマ7.1C5(ATCC登録番号PTA−3900)によって産生される抗体と同じ重鎖ポリペプチド配列および軽鎖ポリペプチド配列を含む、請求項1に記載の抗体。
- 前記抗体とαvβ6との間での結合が、二価カチオン依存性である、請求項1に記載の抗体。
- 前記二価カチオンが、Ca2+、Mg2+またはMn2+である、請求項9に記載の抗体。
- 前記抗体とαvβ6との間での結合が、二価カチオン非依存性である、請求項1に記載の抗体。
- 抗αvβ6抗体であって、重鎖の相補性決定領域(CDR)1、2および3が、それぞれ、配列番号1、4および7の配列から本質的になり、そして軽鎖CDRが、必要に応じて、それぞれ、配列番号10、13および15の配列から本質的になる、抗αvβ6抗体。
- 抗αvβ6抗体であって、重鎖の相補性決定領域(CDR)1、2および3が、それぞれ、配列番号3、5および8の配列から本質的になり、そして軽鎖CDRが、必要に応じて、それぞれ、配列番号11、14および17の配列から本質的になる、抗αvβ6抗体。
- 抗αvβ6抗体であって、重鎖の相補性決定領域(CDR)1、2および3が、それぞれ、配列番号3、6および9の配列から本質的になり、そして軽鎖CDRが、必要に応じて、それぞれ、配列番号12、14および18の配列から本質的になる、抗αvβ6抗体。
- 抗αvβ6抗体であって、重鎖の相補性決定領域(CDR)1、2および3が、それぞれ、配列番号2、46および47の配列から本質的になり、そして軽鎖CDRが、必要に応じて、それぞれ、配列番号48、13および16の配列から本質的になる、抗αvβ6抗体。
- 抗αvβ6抗体であって、重鎖の相補性決定領域(CDR)1、2および3が、それぞれ、配列番号49、51および53の配列から本質的になり、そして軽鎖CDRが、必要に応じて、それぞれ、配列番号55、57および59の配列から本質的になる、抗αvβ6抗体。
- 抗αvβ6抗体であって、重鎖の相補性決定領域(CDR)1、2および3が、それぞれ、配列番号50、52および54の配列から本質的になり、そして軽鎖CDRが、必要に応じて、それぞれ、配列番号56、58および60の配列から本質的になる、抗αvβ6抗体。
- 抗αvβ6抗体であって、配列番号19〜36および61〜62のいずれか1つの重鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号19の重鎖可変ドメイン配列および配列番号37の軽鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号20または21の重鎖可変ドメイン配列および配列番号38の軽鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号22の重鎖可変ドメイン配列および配列番号43の軽鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号23の重鎖可変ドメイン配列および配列番号44の軽鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号24の重鎖可変ドメイン配列および配列番号45の軽鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号25または26の重鎖可変ドメイン配列および配列番号42の軽鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号27、28または29の重鎖可変ドメイン配列および配列番号39の軽鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号34または35の重鎖可変ドメイン配列および配列番号40の軽鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号36の重鎖可変ドメイン配列および配列番号41の軽鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号61の重鎖可変ドメイン配列および配列番号63の軽鎖可変ドメイン配列を含む、抗体。
- 抗αvβ6抗体であって、配列番号62の重鎖可変ドメイン配列および配列番号64の軽鎖可変ドメイン配列を含む、抗体。
- モノクローナル抗体であって、αvβ6に特異的に結合するが、潜伏関連ペプチド(LAP)へのαvβ6の結合を阻害しない、抗体。
- 前記抗体が、ハイブリドーマ6.2A1(ATCC登録番号PTA−3896)によって産生される抗体と同じ重鎖ポリペプチド配列および軽鎖ポリペプチド配列を含む、請求項30に記載の抗体。
- 前記抗体が、ハイブリドーマ6.2E5(ATCC登録番号PTA−3897)によって産生される抗体と同じ重鎖ポリペプチド配列および軽鎖ポリペプチド配列を含む、請求項30に記載の抗体。
- 哺乳動物においてαvβ6によって媒介される疾患を予防または処置するための組成物であって、請求項1〜32のいずれか1項に記載の抗体および薬学的に受容可能なキャリアを含む、組成物。
- 前記抗体が、細胞傷害性薬剤に結合されている、請求項33に記載の組成物。
- 前記抗体が、カチオン依存性抗体である、請求項33に記載の組成物。
- αvβ6によって媒介される疾患を有するかまたは該疾患を有する危険性がある被験体を処置するための、請求項33に記載の組成物であって、該組成物は、該疾患を緩和するかまたは該疾患の発症を延期するように、該被験体に投与されるように処方されている、組成物。
- 前記被験体がヒトである、請求項36に記載の組成物。
- 前記疾患が、線維症である、請求項36に記載の組成物。
- 前記線維症が、強皮症、瘢痕、肝臓線維症、腎臓線維症、または肺線維症である、請求項38に記載の組成物。
- 前記疾患が、乾癬である、請求項36に記載の組成物。
- 前記疾患が、癌である、請求項36に記載の組成物。
- 前記癌が、上皮癌である、請求項41に記載の組成物。
- 前記癌が、口腔癌、皮膚癌、頸部癌、卵巣癌、咽頭癌、喉頭癌、食道癌、肺癌、乳癌、腎臓癌、または結腸直腸癌である、請求項41に記載の組成物。
- 前記疾患が、アルポート症候群である、請求項36に記載の組成物。
- 哺乳動物由来の組織サンプル中のαvβ6を検出する方法であって、該組織サンプルを、請求項1または30に記載の抗体と接触させる工程を包含する、方法。
- 前記抗体が、6.2A1(ATCC登録番号PTA 3896)および6.2E5(ATCC登録番号PTA 3897)からなる群より選択される、請求項45に記載の方法。
- ハイブリドーマ6.1A8(ATCC登録番号PTA−3647)の細胞。
- ハイブリドーマ6.2B10(ATCC登録番号PTA−3648)の細胞。
- ハイブリドーマ6.3G9(ATCC登録番号PTA−3649)の細胞。
- ハイブリドーマ6.8G6(ATCC登録番号PTA−3645)の細胞。
- ハイブリドーマ6.2B1(ATCC登録番号PTA−3646)の細胞。
- ハイブリドーマ6.2A1(ATCC登録番号PTA−3896)の細胞
- ハイブリドーマ6.2E5(ATCC登録番号PTA−3897)の細胞。
- ハイブリドーマ7.1 G10(ATCC登録番号PTA−3898)の細胞。
- ハイブリドーマ7.7G5(ATCC登録番号PTA−3899)の細胞。
- ハイブリドーマ7.1 C5(ATCC登録番号PTA−3900)の細胞。
- 単離された核酸であって、配列番号19〜45および61〜64のいずれか1つについてのコード配列を含む、核酸。
- 単離されたポリペプチドであって、配列番号19〜45および61〜64のいずれか1つのアミノ酸配列を含む、ポリペプチド。
- モノクローナル抗体であって、ハイブリドーマ6.2B10(ATCC登録番号PTA−3648)によって産生される抗体と同じ重鎖ポリペプチド配列および軽鎖ポリペプチド配列を含む、抗体。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36499102P | 2002-03-13 | 2002-03-13 | |
US42628602P | 2002-11-13 | 2002-11-13 | |
PCT/US2003/008048 WO2003100033A2 (en) | 2002-03-13 | 2003-03-13 | ANTI-αvβ6 ANTIBODIES |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009011451A Division JP2009100763A (ja) | 2002-03-13 | 2009-01-21 | 抗αvβ6抗体 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005528099A JP2005528099A (ja) | 2005-09-22 |
JP2005528099A5 true JP2005528099A5 (ja) | 2006-04-27 |
JP4473117B2 JP4473117B2 (ja) | 2010-06-02 |
Family
ID=29586753
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004508275A Expired - Fee Related JP4473117B2 (ja) | 2002-03-13 | 2003-03-13 | 抗αvβ6抗体 |
JP2009011451A Withdrawn JP2009100763A (ja) | 2002-03-13 | 2009-01-21 | 抗αvβ6抗体 |
JP2012177348A Expired - Lifetime JP5616932B2 (ja) | 2002-03-13 | 2012-08-09 | 抗αvβ6抗体 |
JP2012177349A Withdrawn JP2012228269A (ja) | 2002-03-13 | 2012-08-09 | 抗αvβ6抗体 |
JP2014234208A Withdrawn JP2015091807A (ja) | 2002-03-13 | 2014-11-19 | 抗αvβ6抗体 |
JP2015048289A Withdrawn JP2015126743A (ja) | 2002-03-13 | 2015-03-11 | 抗αvβ6抗体 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009011451A Withdrawn JP2009100763A (ja) | 2002-03-13 | 2009-01-21 | 抗αvβ6抗体 |
JP2012177348A Expired - Lifetime JP5616932B2 (ja) | 2002-03-13 | 2012-08-09 | 抗αvβ6抗体 |
JP2012177349A Withdrawn JP2012228269A (ja) | 2002-03-13 | 2012-08-09 | 抗αvβ6抗体 |
JP2014234208A Withdrawn JP2015091807A (ja) | 2002-03-13 | 2014-11-19 | 抗αvβ6抗体 |
JP2015048289A Withdrawn JP2015126743A (ja) | 2002-03-13 | 2015-03-11 | 抗αvβ6抗体 |
Country Status (23)
Country | Link |
---|---|
US (4) | US7465449B2 (ja) |
EP (4) | EP2287198A3 (ja) |
JP (6) | JP4473117B2 (ja) |
KR (1) | KR101098109B1 (ja) |
CN (4) | CN1646160A (ja) |
AR (1) | AR038970A1 (ja) |
AU (1) | AU2003261071C1 (ja) |
BR (1) | BRPI0308585B8 (ja) |
CA (1) | CA2478833C (ja) |
CL (8) | CL2010000788A1 (ja) |
EA (1) | EA011853B1 (ja) |
ES (1) | ES2389037T3 (ja) |
HK (2) | HK1074381A1 (ja) |
IL (4) | IL164021A0 (ja) |
IS (1) | IS7443A (ja) |
ME (1) | ME00804B (ja) |
MX (1) | MXPA04008870A (ja) |
MY (2) | MY147019A (ja) |
NO (1) | NO334834B1 (ja) |
NZ (2) | NZ535425A (ja) |
PL (1) | PL216223B1 (ja) |
RS (1) | RS52488B (ja) |
WO (1) | WO2003100033A2 (ja) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME00804B (me) * | 2002-03-13 | 2012-03-20 | Biogen Idec Inc | Anti-alpha v beta 6 antitela |
US20040048312A1 (en) * | 2002-04-12 | 2004-03-11 | Ronghao Li | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
CA2434668A1 (en) | 2003-07-04 | 2005-01-04 | Laurence Mulard | Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a |
CN104072614B (zh) * | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
AU2012258386B2 (en) * | 2005-07-08 | 2014-08-07 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
US20100267060A1 (en) * | 2006-01-17 | 2010-10-21 | Biosite Incorporated | High sensitivity secretagogin assays and their uses for diagnosis and/or prognosis |
EP2046374A4 (en) | 2006-07-10 | 2010-05-05 | Biogen Idec Inc | COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS |
AU2007348941B2 (en) * | 2006-08-03 | 2011-08-04 | Medimmune Limited | Antibodies directed to alphaVbeta6 and uses thereof |
CA2665885A1 (en) * | 2006-10-19 | 2008-12-04 | The Regents Of The University Of California | Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6 |
LT2164992T (lt) * | 2007-05-30 | 2016-09-12 | Lpath, Inc. | Lizofosfatido rūgšties kompozicijos ir prisirišimo būdai |
US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
US20110064744A1 (en) * | 2007-05-30 | 2011-03-17 | Sabbadini Roger A | Prevention and treatment of pain using antibodies to lysophosphatidic acid |
ES2639016T3 (es) * | 2007-11-16 | 2017-10-25 | The Rockefeller University | Anticuerpos específicos para la forma protofibrilar de proteína beta-amiloide |
BRPI0912570B8 (pt) | 2008-05-07 | 2021-05-25 | Argos Therapeutics Inc | anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos |
AU2009245724A1 (en) * | 2008-05-09 | 2009-11-12 | Ablynx N.V. | Amino acid sequences directed against integrins and uses thereof |
CA2724231A1 (en) | 2008-05-15 | 2009-11-19 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도 |
WO2011020529A2 (en) * | 2009-08-19 | 2011-02-24 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
WO2011119524A1 (en) * | 2010-03-22 | 2011-09-29 | The University Of North Carolina At Chapel Hill | Novel targets for regulation of angiogenesis |
BR112012027900A2 (pt) | 2010-04-30 | 2020-05-12 | Alexion Pharmaceuticals, Inc. | Anticorpos anti-c5a e métodos para usar os anticorpos |
WO2012143495A2 (de) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Neue binder-wirkstoff konjugate (adcs) und ihre verwendung |
US8852592B2 (en) | 2011-05-10 | 2014-10-07 | Biocare Medical, Llc | Systems and methods for anti-PAX8 antibodies |
CN104220094A (zh) * | 2012-02-17 | 2014-12-17 | 西雅图基因公司 | 针对整联蛋白αvβ6的抗体和使用该抗体治疗癌症 |
US10316103B1 (en) | 2012-03-30 | 2019-06-11 | Biocare Medical, Llc | Systems and methods for anti-Uroplakin III antibodies |
DK2900265T3 (en) | 2012-09-27 | 2018-08-20 | Biocare Medical Llc | Anti-Uroplakin II Antibodies, Systems and Methods |
PT2905335T (pt) * | 2012-10-03 | 2018-03-12 | Chiome Bioscience Inc | Anticorpo anti-hdlk-1 tendo uma atividade anti-tumoral in vivo |
CA2885340C (en) | 2012-10-12 | 2016-11-08 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
WO2014100220A2 (en) | 2012-12-18 | 2014-06-26 | Biocare Medical, Llc | Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer |
EP2962113B1 (en) | 2013-02-28 | 2019-04-03 | Biocare Medical, LLC | Anti-p40 antibodies systems and methods |
KR102066319B1 (ko) | 2013-03-13 | 2020-01-14 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨쥬게이트 |
WO2014144466A1 (en) * | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Anti-alpha v beta 6 antibodies and uses thereof |
US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
RU2725825C2 (ru) | 2013-08-30 | 2020-07-06 | Иммьюноджен Инк. | Антитела и методы анализа для обнаружения рецептора фолиевой кислоты 1 |
KR102150616B1 (ko) | 2013-09-12 | 2020-09-03 | 삼성전자주식회사 | c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도 |
JP6527508B2 (ja) * | 2013-10-01 | 2019-06-05 | メディミューン リミテッド | αVβ6を過剰発現する癌を治療及び診断する方法 |
WO2015051320A2 (en) | 2013-10-03 | 2015-04-09 | Biocare Medical, Llc | Anti-sox10 antibody systems and methods |
CN104721225A (zh) | 2013-12-19 | 2015-06-24 | 高露洁-棕榄公司 | 口腔护理组合物 |
EP3086814B1 (de) | 2013-12-23 | 2020-06-24 | Bayer Pharma Aktiengesellschaft | Binder-konjugate (adcs) mit ksp-inhibitoren |
CA2938129A1 (en) * | 2014-02-03 | 2015-08-06 | Cangene Corporation | Humanized beta-amyloid binding molecules and uses thereof |
SG10201913680PA (en) | 2014-05-29 | 2020-03-30 | Macrogenics Inc | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
AU2016282723B2 (en) | 2015-06-22 | 2021-09-23 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups |
CN107921288A (zh) | 2015-06-23 | 2018-04-17 | 拜耳医药股份有限公司 | Ksp抑制剂的靶向缀合物 |
CN108135986B (zh) * | 2015-08-13 | 2022-07-29 | 纽约大学 | 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途 |
EP3349796A4 (en) | 2015-09-17 | 2019-05-29 | ImmunoGen, Inc. | THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
GB201604681D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
EP3432934B1 (de) | 2016-03-24 | 2022-02-23 | Bayer Pharma Aktiengesellschaft | Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen |
EP3919518A1 (en) | 2016-06-15 | 2021-12-08 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies |
US20190284259A1 (en) * | 2016-07-22 | 2019-09-19 | Georgia State University Research Foundation | Monoclonal Antibodies to B Virus And Their Use For Identification Of B Virus Specific Reactive Peptides |
WO2018069289A1 (en) | 2016-10-11 | 2018-04-19 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
KR102486434B1 (ko) | 2016-11-08 | 2023-01-09 | 리아타 파마슈티컬즈 홀딩스, 엘엘씨 | 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법 |
CA3044526A1 (en) | 2016-12-07 | 2018-06-14 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
CN116712540A (zh) | 2016-12-14 | 2023-09-08 | 比奥拉治疗股份有限公司 | 使用整联蛋白抑制剂治疗胃肠道疾病 |
IL310558A (en) | 2016-12-21 | 2024-03-01 | Bayer Pharma AG | Drug-antibody conjugates with enzymatically cleavable groups |
CN110072556B (zh) | 2016-12-21 | 2023-05-02 | 拜耳制药股份公司 | 具有ksp抑制剂的特异性抗体药物缀合物(adc) |
CN110312533B (zh) | 2016-12-21 | 2023-11-03 | 拜耳公司 | 具有酶促可裂解的基团的细胞毒性活性剂的前药 |
GB201720989D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
MX2020012034A (es) | 2018-05-11 | 2021-04-12 | Glaxosmithkline Ip Dev Ltd | Inhibidores de furina. |
US20220111065A1 (en) | 2018-05-23 | 2022-04-14 | Adc Therapeutics Sa | Molecular adjuvant |
US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
EP3883636A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
GB201908536D0 (en) | 2019-06-13 | 2019-07-31 | Glaxosmithkline Ip Dev Ltd | Compounds |
WO2021108302A1 (en) * | 2019-11-26 | 2021-06-03 | Children's Hospital Medical Center | Cela-1 inhibition for treatment of lung disease |
CN114828887A (zh) | 2019-12-05 | 2022-07-29 | 思进公司 | 抗-αVβ6抗体和抗体-药物偶联物 |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
CN117396508A (zh) * | 2021-01-26 | 2024-01-12 | 加利福尼亚大学董事会 | 用于治疗和预防与avb8整合素相关的疾病的组合物和方法 |
JP2024506291A (ja) | 2021-02-03 | 2024-02-13 | ビーピー アセット ヴイ,インコーポレーテッド | 吸入用のフューリンインヒビターの製剤 |
GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
WO2023194895A1 (en) | 2022-04-06 | 2023-10-12 | Glaxosmithkline Intellectual Property Development Limited | Pyrrol derivatives as inhibitors of apolipoprotein l-1 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US5223493A (en) | 1984-12-28 | 1993-06-29 | Alcon Laboratories, Inc. | Anti-inflammatory compounds for ophthalmic use |
US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
NZ222509A (en) | 1986-11-19 | 1993-03-26 | Oncogen | Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen |
US5019368A (en) * | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5804381A (en) * | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
GB9009549D0 (en) * | 1990-04-27 | 1990-06-20 | Celltech Ltd | Recombinant antibody and method |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
US5420120A (en) | 1993-12-17 | 1995-05-30 | Alcon Laboratories, Inc. | Anti-inflammatory glucocorticoid compounds for topical ophthalmic use |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
US6417324B1 (en) * | 2000-04-21 | 2002-07-09 | Tripep Ab | Synthetic peptides that bind to the hepatitis B virus core and e antigens |
DE69531187T2 (de) * | 1994-12-20 | 2004-04-22 | Merck Patent Gmbh | Monoklonaler Antikörper gegen das Alpha-V-Integrin |
US5688960A (en) | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
US5696267A (en) | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
US5719156A (en) | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
AU6773596A (en) | 1995-08-17 | 1997-03-12 | Protein Design Labs, Inc. | Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage |
DK1143006T3 (da) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
EP1916300A1 (en) | 1995-08-29 | 2008-04-30 | Kirin Pharma Kabushiki Kaisha | Chimeric animal and method for producing the same |
US5691362A (en) | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
ATE248192T1 (de) * | 1996-06-07 | 2003-09-15 | Neorx Corp | HUMANISIERTE ANTIKÖRPER DIE AN DAS GLEICHE ANTIGEN WIE ANTIKÖRPER NR-LU-13 BINDEN UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN |
AU6721696A (en) | 1996-07-15 | 1998-03-06 | Human Genome Sciences, Inc. | Cd44-like protein |
US5789422A (en) | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
US5783579A (en) | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
NZ515955A (en) * | 1997-08-08 | 2003-04-29 | Univ California | Hybridoma producing a monoclonal antibody against beta-6 integrin |
PL341569A1 (en) | 1998-01-23 | 2001-04-23 | Merck Patent Gmbh | Monoclonal anti-alphav-integrin antibody and application thereof as an inhibitore of alphavbeta6-integrin to fibronectin bond |
JP2002533064A (ja) | 1998-12-19 | 2002-10-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | インテグリンαvβ6阻害剤 |
US7163681B2 (en) | 2000-08-07 | 2007-01-16 | Centocor, Inc. | Anti-integrin antibodies, compositions, methods and uses |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
DE10063173A1 (de) | 2000-12-18 | 2002-06-20 | Merck Patent Gmbh | Harnstoff- und Urethanderivate |
PL367324A1 (en) | 2001-04-13 | 2005-02-21 | Biogen, Inc. | Antibodies to vla-1 |
DE10118550A1 (de) | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | Liganden des Integrins alpha¶nu¶beta¶6¶ |
GB2380127A (en) | 2001-09-26 | 2003-04-02 | Isis Innovation | Treatment of chronic joint inflammation |
EP2289941A3 (en) | 2002-02-25 | 2012-01-18 | Elan Pharmaceuticals Inc. | Administration of agents for the treatment of inflammation |
ME00804B (me) | 2002-03-13 | 2012-03-20 | Biogen Idec Inc | Anti-alpha v beta 6 antitela |
US20040048312A1 (en) | 2002-04-12 | 2004-03-11 | Ronghao Li | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
WO2003097615A1 (en) | 2002-05-17 | 2003-11-27 | Scios, Inc. | TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS |
JP4741242B2 (ja) | 2002-11-26 | 2011-08-03 | アボット バイオセラピューティクス コーポレイション | 新脈管形成を調節するα5β1インテグリンへのキメラ及びヒト化抗体 |
US20040253311A1 (en) | 2002-12-18 | 2004-12-16 | Roger Berlin | Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines |
CA2540730C (en) | 2003-10-01 | 2012-08-21 | Merck Patent Gmbh | Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
US20070292887A1 (en) | 2003-11-04 | 2007-12-20 | Bayer Pharmaceuticals Corporation | Immunohistochemical Methods |
CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
EP2046374A4 (en) | 2006-07-10 | 2010-05-05 | Biogen Idec Inc | COMPOSITIONS AND METHODS FOR GROWTH INHIBITION OF SMAD4-DEFICIENT TUMORS |
CA2665885A1 (en) | 2006-10-19 | 2008-12-04 | The Regents Of The University Of California | Treatment and prevention of chronic asthma using antagonists of integrin .alpha.nu.beta.6 |
GB0803192D0 (en) | 2008-02-22 | 2008-04-02 | Mubio Products Bv | SCLC biomarker panel |
PL2368118T3 (pl) | 2008-12-23 | 2014-03-31 | Merck Patent Gmbh | Biomarkery dla inhibitorów z aktywnością antyangiogeniczną |
WO2012031008A2 (en) | 2010-08-31 | 2012-03-08 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
ES2875535T3 (es) | 2012-03-29 | 2021-11-10 | Biogen Ma Inc | Biomarcadores para su uso en aplicaciones de terapia de integrina |
-
2003
- 2003-03-13 ME MEP-2009-200A patent/ME00804B/me unknown
- 2003-03-13 AR ARP030100885A patent/AR038970A1/es not_active Application Discontinuation
- 2003-03-13 JP JP2004508275A patent/JP4473117B2/ja not_active Expired - Fee Related
- 2003-03-13 ES ES03755325T patent/ES2389037T3/es not_active Expired - Lifetime
- 2003-03-13 RS YU80704A patent/RS52488B/en unknown
- 2003-03-13 EP EP10013155A patent/EP2287198A3/en not_active Ceased
- 2003-03-13 CA CA2478833A patent/CA2478833C/en not_active Expired - Lifetime
- 2003-03-13 EA EA200401198A patent/EA011853B1/ru unknown
- 2003-03-13 KR KR1020047014307A patent/KR101098109B1/ko active IP Right Grant
- 2003-03-13 WO PCT/US2003/008048 patent/WO2003100033A2/en active Application Filing
- 2003-03-13 BR BRPI0308585A patent/BRPI0308585B8/pt not_active IP Right Cessation
- 2003-03-13 MY MYPI20030886A patent/MY147019A/en unknown
- 2003-03-13 IL IL16402103A patent/IL164021A0/xx unknown
- 2003-03-13 PL PL372662A patent/PL216223B1/pl unknown
- 2003-03-13 CN CNA038089068A patent/CN1646160A/zh active Pending
- 2003-03-13 EP EP03755325A patent/EP1490110B1/en not_active Expired - Lifetime
- 2003-03-13 US US10/507,662 patent/US7465449B2/en not_active Expired - Lifetime
- 2003-03-13 MY MYPI20094390A patent/MY154009A/en unknown
- 2003-03-13 CN CN2012100664380A patent/CN102659946A/zh active Pending
- 2003-03-13 CN CN201210067222.6A patent/CN102924598B/zh not_active Expired - Lifetime
- 2003-03-13 AU AU2003261071A patent/AU2003261071C1/en not_active Expired
- 2003-03-13 CN CN201510182148.6A patent/CN104805090A/zh active Pending
- 2003-03-13 EP EP10012545A patent/EP2336185A1/en not_active Withdrawn
- 2003-03-13 NZ NZ535425A patent/NZ535425A/en not_active IP Right Cessation
- 2003-03-13 MX MXPA04008870A patent/MXPA04008870A/es active IP Right Grant
- 2003-03-13 EP EP10013156.4A patent/EP2287199B1/en not_active Expired - Lifetime
- 2003-12-13 NZ NZ563951A patent/NZ563951A/en not_active IP Right Cessation
-
2004
- 2004-09-09 IS IS7443A patent/IS7443A/is unknown
- 2004-09-12 IL IL164021A patent/IL164021A/en active IP Right Grant
- 2004-09-12 IL IL225633A patent/IL225633B/en unknown
- 2004-10-13 NO NO20044347A patent/NO334834B1/no not_active IP Right Cessation
-
2005
- 2005-06-28 HK HK05105402.6A patent/HK1074381A1/xx not_active IP Right Cessation
-
2008
- 2008-10-29 US US12/260,510 patent/US8153126B2/en not_active Expired - Lifetime
-
2009
- 2009-01-21 JP JP2009011451A patent/JP2009100763A/ja not_active Withdrawn
-
2010
- 2010-07-23 CL CL2010000788A patent/CL2010000788A1/es unknown
- 2010-07-23 CL CL2010000789A patent/CL2010000789A1/es unknown
- 2010-07-23 CL CL2010000792A patent/CL2010000792A1/es unknown
- 2010-07-23 CL CL2010000785A patent/CL2010000785A1/es unknown
- 2010-07-23 CL CL2010000787A patent/CL2010000787A1/es unknown
- 2010-07-23 CL CL2010000786A patent/CL2010000786A1/es unknown
- 2010-07-23 CL CL2010000791A patent/CL2010000791A1/es unknown
- 2010-07-23 CL CL2010000790A patent/CL2010000790A1/es unknown
-
2012
- 2012-04-10 US US13/443,261 patent/US20120251532A1/en not_active Abandoned
- 2012-08-09 JP JP2012177348A patent/JP5616932B2/ja not_active Expired - Lifetime
- 2012-08-09 JP JP2012177349A patent/JP2012228269A/ja not_active Withdrawn
-
2013
- 2013-04-08 IL IL225633A patent/IL225633A0/en unknown
-
2014
- 2014-07-28 US US14/444,701 patent/US9745376B2/en not_active Expired - Lifetime
- 2014-11-19 JP JP2014234208A patent/JP2015091807A/ja not_active Withdrawn
-
2015
- 2015-03-11 JP JP2015048289A patent/JP2015126743A/ja not_active Withdrawn
-
2016
- 2016-01-22 HK HK16100767.3A patent/HK1213007A1/zh unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005528099A5 (ja) | ||
JP2009541204A5 (ja) | ||
JP2022079549A5 (ja) | ||
JP2007536932A5 (ja) | ||
JP2004517611A5 (ja) | ||
JP2009517057A5 (ja) | ||
RU2009101788A (ru) | Направленные на опухоль моноклональные антитела против fzd10 и их применение | |
JP2019107018A5 (ja) | ||
JP2010523096A5 (ja) | ||
JP2005533493A5 (ja) | ||
JP2005225884A5 (ja) | ||
RU2009120052A (ru) | Композиции и способы связывания сфингозин-1-фосфата | |
JP2008529497A5 (ja) | ||
JP2005538701A5 (ja) | ||
JP2010533498A5 (ja) | ||
JP2020526478A5 (ja) | ||
JP2006507013A5 (ja) | ||
JP2010501164A5 (ja) | ||
JP2020514310A5 (ja) | ||
NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
JP2011528561A5 (ja) | ||
RU2012112829A (ru) | Анти-gitr-антитела | |
JP2014524746A5 (ja) | ||
RU2015126533A (ru) | Анти-cd47 антитела и способы их применения | |
JP2010536886A5 (ja) |